kynurenine has been researched along with Cardiac Failure in 10 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy." | 8.31 | Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023) |
| "Metabolites of the kynurenine pathway (mKP) relate to important aspects of heart failure pathophysiology, such as inflammation, energy-homeostasis, apoptosis, and oxidative stress." | 7.96 | Plasma kynurenines and prognosis in patients with heart failure. ( Giil, LM; Lund, A; Midttun, Ø; Nordrehaug, JE; Nygård, O; Pedersen, EK; Slettom, G; Solvang, SH; Ueland, PM; Ulvik, A, 2020) |
| "It was our objective to increase the body of data regarding the value of kynurenine as a biomarker in chronic heart failure (CHF)." | 7.91 | Plasma Kynurenine Predicts Severity and Complications of Heart Failure and Associates with Established Biochemical and Clinical Markers of Disease. ( Armbruster, FP; Bankovic, D; Boschann, F; Dschietzig, TB; Kellner, KH; Klüsener, R; Meinitzer, A; Melzer, C; Mitrovic, V; Ruppert, J; Sasse, K, 2019) |
| "Kynurenine is a circulating metabolite from the essential amino acid tryptophan." | 6.82 | Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). ( Anker, SD; Doehner, W; Dschietzig, TB; Ebner, N; Konishi, M; Schefold, JC; Springer, J; von Haehling, S, 2016) |
| "Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy." | 4.31 | Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023) |
| "Metabolites of the kynurenine pathway (mKP) relate to important aspects of heart failure pathophysiology, such as inflammation, energy-homeostasis, apoptosis, and oxidative stress." | 3.96 | Plasma kynurenines and prognosis in patients with heart failure. ( Giil, LM; Lund, A; Midttun, Ø; Nordrehaug, JE; Nygård, O; Pedersen, EK; Slettom, G; Solvang, SH; Ueland, PM; Ulvik, A, 2020) |
| "It was our objective to increase the body of data regarding the value of kynurenine as a biomarker in chronic heart failure (CHF)." | 3.91 | Plasma Kynurenine Predicts Severity and Complications of Heart Failure and Associates with Established Biochemical and Clinical Markers of Disease. ( Armbruster, FP; Bankovic, D; Boschann, F; Dschietzig, TB; Kellner, KH; Klüsener, R; Meinitzer, A; Melzer, C; Mitrovic, V; Ruppert, J; Sasse, K, 2019) |
| "Kynurenine is a circulating metabolite from the essential amino acid tryptophan." | 2.82 | Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). ( Anker, SD; Doehner, W; Dschietzig, TB; Ebner, N; Konishi, M; Schefold, JC; Springer, J; von Haehling, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bekfani, T | 1 |
| Bekhite, M | 1 |
| Neugebauer, S | 1 |
| Derlien, S | 1 |
| Hamadanchi, A | 1 |
| Nisser, J | 1 |
| Hilse, MS | 1 |
| Haase, D | 1 |
| Kretzschmar, T | 1 |
| Wu, MF | 1 |
| Lichtenauer, M | 1 |
| Kiehntopf, M | 1 |
| von Haehling, S | 2 |
| Schlattmann, P | 1 |
| Lehmann, G | 1 |
| Franz, M | 1 |
| Möbius-Winkler, S | 1 |
| Schulze, C | 1 |
| Bai, L | 1 |
| Han, X | 1 |
| Kee, HJ | 1 |
| He, X | 1 |
| Kim, SH | 1 |
| Jeon, MJ | 1 |
| Zhou, H | 1 |
| Jeong, SM | 1 |
| Kee, SJ | 1 |
| Jeong, MH | 1 |
| Lund, A | 1 |
| Nordrehaug, JE | 1 |
| Slettom, G | 1 |
| Solvang, SH | 1 |
| Pedersen, EK | 1 |
| Midttun, Ø | 1 |
| Ulvik, A | 1 |
| Ueland, PM | 1 |
| Nygård, O | 1 |
| Giil, LM | 1 |
| Sousa, A | 1 |
| Ribeiro, C | 1 |
| Gonçalves, VMF | 1 |
| Barbosa, J | 1 |
| Peixoto, B | 1 |
| Andrade, A | 1 |
| Silva, P | 1 |
| Andrade, JP | 1 |
| Leal, S | 1 |
| Razquin, C | 1 |
| Ruiz-Canela, M | 1 |
| Toledo, E | 1 |
| Hernández-Alonso, P | 1 |
| Clish, CB | 1 |
| Guasch-Ferré, M | 1 |
| Li, J | 1 |
| Wittenbecher, C | 1 |
| Dennis, C | 1 |
| Alonso-Gómez, A | 1 |
| Fitó, M | 1 |
| Liang, L | 1 |
| Corella, D | 1 |
| Gómez-Gracia, E | 1 |
| Estruch, R | 1 |
| Fiol, M | 1 |
| Lapetra, J | 1 |
| Serra-Majem, L | 1 |
| Ros, E | 1 |
| Aros, F | 1 |
| Salas-Salvadó, J | 1 |
| Hu, FB | 1 |
| Martínez-González, MA | 1 |
| Su, J | 1 |
| Wang, J | 1 |
| Ma, Y | 1 |
| Li, Q | 1 |
| Yang, Y | 1 |
| Huang, L | 1 |
| Wang, H | 1 |
| Li, H | 1 |
| Wang, Z | 1 |
| Tong, J | 1 |
| Huang, D | 1 |
| Bai, X | 1 |
| Yu, M | 1 |
| Bu, L | 1 |
| Fei, J | 1 |
| Huang, F | 1 |
| Dschietzig, TB | 2 |
| Kellner, KH | 1 |
| Sasse, K | 1 |
| Boschann, F | 1 |
| Klüsener, R | 1 |
| Ruppert, J | 1 |
| Armbruster, FP | 1 |
| Bankovic, D | 1 |
| Meinitzer, A | 1 |
| Mitrovic, V | 1 |
| Melzer, C | 1 |
| Zhang, Y | 1 |
| Blasco-Colmenares, E | 1 |
| Harms, AC | 1 |
| London, B | 1 |
| Halder, I | 1 |
| Singh, M | 1 |
| Dudley, SC | 1 |
| Gutmann, R | 1 |
| Guallar, E | 1 |
| Hankemeier, T | 1 |
| Tomaselli, GF | 1 |
| Cheng, A | 1 |
| Konishi, M | 1 |
| Ebner, N | 1 |
| Springer, J | 1 |
| Schefold, JC | 1 |
| Doehner, W | 1 |
| Anker, SD | 1 |
| Schroecksnadel, K | 1 |
| Wirleitner, B | 1 |
| Fuchs, D | 1 |
2 trials available for kynurenine and Cardiac Failure
| Article | Year |
|---|---|
Metabolomics of the tryptophan-kynurenine degradation pathway and risk of atrial fibrillation and heart failure: potential modification effect of Mediterranean diet.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Case-Control Studies; Diet, Mediterranean; Female; Hea | 2021 |
Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
Topics: Age Factors; Aged; Body Mass Index; Disease-Free Survival; Female; Heart Failure; Humans; Kidney; Ky | 2016 |
8 other studies available for kynurenine and Cardiac Failure
| Article | Year |
|---|---|
Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker.
Topics: Biomarkers; Heart Failure; Humans; Kynurenine; Metabolomics; Stroke Volume | 2022 |
Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Kynurenine; Kynurenine 3-Monooxygenase; Mice; M | 2023 |
Plasma kynurenines and prognosis in patients with heart failure.
Topics: Aged; Biomarkers; Case-Control Studies; Coronary Artery Disease; Female; Heart Failure; Humans; Kynu | 2020 |
Development and validation of a liquid chromatography method using UV/fluorescence detection for the quantitative determination of metabolites of the kynurenine pathway in human urine: Application to patients with heart failure.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Heart Failure; Humans; Kynurenine; Mal | 2021 |
Inflammation associated with chronic heart failure leads to enhanced susceptibility to depression.
Topics: Animals; Brain; Chronic Disease; Cytokines; Depression; Heart Failure; Hypothalamo-Hypophyseal Syste | 2019 |
Plasma Kynurenine Predicts Severity and Complications of Heart Failure and Associates with Established Biochemical and Clinical Markers of Disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Chronic Disease; Female; Heart Failure; Humans; Immunoassay; Ky | 2019 |
Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.
Topics: Aged; Amines; Arginine; Biomarkers; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Co | 2016 |
Anemia and congestive heart failure.
Topics: Anemia; Causality; Cell Division; Chronic Disease; Comorbidity; Dioxygenases; Heart Failure; Hematop | 2003 |